A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

This study will evaluate safety and tolerability to estimate the MTDand/or recommended dose.

Phase 1

Novartis Pharmaceuticals